[03 March 2014]
Products Affected - Description
Orphenadrine citrate injection, 30 mg/mL, Bedford
2 mL vial, 10 count (NDC 55390-0059-10)
Reason for the Shortage
- Watson stated the shortage was due to production delays.
- Ben Venue has stopped production in its plant in Bedford, Ohio and will close in early 2014. Ben Venue supplies multiple sterile injectable products for Bedford Laboratories. Supplies of product that has already been manufactured will continue to be released until inventory is depleted. Bedford Laboratories has a small number of products manufactured elsewhere that are not affected by this closure.
Orphenadrine citrate injection, 30 mg/mL, Akorn
2 mL vial, 10 count (NDC 17478-0538-02)
Orphenadrine citrate injection, 30 mg/mL, Sagent
2 mL vial, 10 count (NDC 25021-0651-02)
Orphenadrine citrate injection, 30 mg/mL, Watson
2 mL vial, 10 count (NDC 00591-3222-47)
Estimated Resupply Dates
Bedford has orphenadrine 30 mg/mL 2 mL vials on long-term back order and the company cannot estimate a release date. Ben Venue manufactured orphenadrine for Bedford.
March 3, 2014; November 4, 2013; August 8, 2013; May 22, 2013; March 8, 2013; December 19, 2012; September 19, 2012; July 18, 2012; May 22, 2012; March 22, 2012; March 14, 2012; March 2, 2012; February 3, 2012; January 11, 2012, University of Utah, Drug Information Service. Copyright 2013, Drug Information Service, University of Utah, Salt Lake City, UT.
This information is provided through the support of Novation to ASHP solely as a service to its members, which shall not use this information for their further commercial use. The content was prepared by the Drug Information Center of University of Utah. Novation, ASHP, and the University of Utah make no representations or warranties, express or implied, including, but not limited to, any implied warranty of merchantability and/or fitness for a particular purpose, which respect to such information, and specifically disclaim all such warranties. Users of this information are advised that decisions regarding the use of drugs and drug therapies are complex medical decisions and that in using this information, each user must exercise his or her own independent professional judgment. Neither Novation, ASHP nor the University of Utah assumes any liability for persons administering or receiving drugs or other medical care in reliance upon this information, or otherwise in connection with this bulletin. Neither Novation, ASHP nor University of Utah endorses or recommends the use of any drug.
« Back to Drug Shortage Product Bulletins